Compare Amplitude Inc (AMPL) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amplitude Inc vs Inovio Pharmaceuticals Inc — how do they compare? Amplitude Inc trades at $9.21 (market cap $1.22B), while Inovio Pharmaceuticals Inc trades at $1.2 (market cap $97.91M). The key difference: Amplitude Inc is far larger — about 12.5× Inovio Pharmaceuticals Inc's market cap, and Amplitude Inc is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPL | INO | |
|---|---|---|
Market Cap | $1.22B | $97.91M |
Sector | Technology | Health |
52-Week High | $13.04 | $2.87 |
52-Week Low | $5.61 | $1.05 |
Enterprise Value | $1.05B | $68.92M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPL trades at $9.18, down 2.13% over the past day, with a bullish technical signal from moving averages but bearish oscillators. Revenue growth is strong, reaching $343.21M in 2025, yet the company remains unprofitable with a net income margin of -25.11%. Analyst consensus is bullish with a $9.25 price target, though recent news includes multiple law firm fraud investigations and a Bank of America downgrade citing profitability concerns.
The outlook hinges on AMPL's ability to translate robust revenue growth into profitability amid competitive pressures. Investment opportunity lies in potential margin expansion and market share gains, but risks include ongoing legal scrutiny, execution challenges, and persistent negative cash flows. The stock's near-term direction will likely be driven by upcoming earnings results and clarity on the fraud allegations.
INO trades at $1.18, down 0.84% with bearish technical signals. The company shows minimal revenue of $65K against massive losses, with a net margin of -130,000% and negative cash flow. Recent news highlights an active FDA review for INO-3107 with an October 2026 decision date, while multiple law firms investigate potential fiduciary breaches by directors.
The investment case hinges on the binary FDA approval of INO-3107. While analyst consensus is 53% buy-rated, fundamental metrics are deeply negative. Key risks include clinical trial outcomes, cash burn, and legal scrutiny. Upside depends entirely on successful drug commercialization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amplitude Inc
Amplitude Inc is pioneering a new category of software called digital optimization. The company's digital optimization system serves as the command center for businesses to connect digital products to business outcomes.
Read more on AMPL →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
